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Abstract: Doxorubicin (DOX) is widely used in combination cocktails for treatment of childhood hematological cancers 
and solid tumors. A major factor limiting DOX usage is DOX-induced cardiotoxicity. However, it is not known whether 
protectants like dexrazoxane (DXR) and amifostine (AMF) can prevent DOX-mediated bone damage. The present study 
investigated whether administration of AMF alone or in combination with DXR would prevent any DOX-mediated bone 
damage. Male rat pups were treated with DOX, DXR, AMF, and their combinations. On neonate day 38, the bone mineral 
density (BMD), bone mineral content (BMC) and the micro-architecture of the lumbar vertebrae were analyzed. We have 
shown that when male rats are treated with DOX, DXR, DOX+DXR, AMF, DOX+AMF or DOX+DXR+AMF, there is a 
decrease in lumbar vertebral BMD (p<0.05). Furthermore, the relative bone volume (BV/TV) was decreased by DXR, 
DOX+DXR, and DOX+AMF treatments. Interestingly, DOX+AMF significantly increased BV/TV when compared to 
DXR treatment (p<0.04). The trabecular number (Tb.N) decreased with DXR and DOX+DXR and increased with 
DOX+AMF treatments. This information will be useful in designing better cancer combination therapies that do not lead 
to vertebrae deterioration. 
INTRODUCTION 
  The strength of adult bone reflects factors that regulate 
bone quality (architecture) and density (bone mass or quan-
tity of calcium deposited/unit of bone) acquired during 
childhood and adolescence. Near-maximal or peak bone 
mass of the vertebrae and femurs is achieved at the comple-
tion of pubertal development [1]. Bone mineral density 
(BMD) and bone mineral content (BMC) measurements us-
ing dual-energy X-Ray absorptiometry (DXA) are widely 
used to measure bone density and determine fracture risk for 
osteoporosis [2-5]. Quantitative assessment of micro-
architectural characteristics, such as relative bone volume 
(BV/TV), trabecular number (Tb.N), trabecular separation 
(Tb.Sp), and micro computed tomography scanner (Micro 
CT) are used to estimate bone strength [3]. 
  Chemotherapies administered to children with cancer have 
the potential for long-term negative effects on bone [6] and 
can cause osteopenia during treatment [7]. The reduced height 
and mineralization, and the increased bone fragility found in 
cancer survivors can be caused by several factors that include 
nutritional deficiencies, the malignancy itself, radiation, corti-
costeroids, and direct action of anti-cancer drugs on bone [7, 
8]. Current treatments of childhood hematological cancers and 
solid tumors can involve the anthracycline antibiotic doxoru-
bicin (DOX, Adriamycin™) in combination cocktails [9, 10]. 
DOX-induced cell killing is due to increases in oxidative 
stress causing apoptosis, as well as to its ability to bind and  
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stabilize DNA topoisomerase II cleavable complexes [11, 12]. 
A major factor limiting DOX usage is DOX-induced car-
diotoxicity. Indeed, some studies suggest that young females 
have a greater incidence for DOX-induced cardiotoxicity than 
young males [13-15]. Dexrazoxane (DXR, ICRF-187, Zine-
card™), also known as (+)-1,2-bis (3,5-dioxopiperazinyl-1-yl) 
propane, is the water soluble S-(+)-enantiomer of the racemic 
razoxane (ICRF-159) and was originally designed as an anti-
cancer agent [16, 17]. DXR can reduce or prevent DOX-
induced cardiotoxicity in children [18-20]. Amifostine (AMF, 
Ethyol™) is a cytoprotective agent that protects a broad range 
of normal tissues from the toxic effects of chemotherapy and 
radiotherapy without attenuating the tumor response [21]. 
  The effect of DOX, with or without DXR and/or AMF, on 
bone in children is not well understood. We have previously 
shown a significant decrease in the right femoral and lumbar 
vertebral BMD of female rats treated with AMF, AMF+DOX 
or AMF+DXR+DOX [22]. However, the effect of AMF alone 
or in combination therapies on male vertebrae is not well un-
derstood. Since some differences in drug response have been 
observed between the genders [13-15, 23], the present work 
sought to determine whether administration of AMF alone or 
in combination with DXR would prevent any DOX-mediated 
bone damage and deterioration of vertebrae bone micro archi-
tecture in the young growing male rats. 
MATERIALS AND METHODS 
Drugs 
  Doxorubicin (DOX, Adriamycin™, Adria) and Dexrazox-
ane (DXR, Zinecard™, Pharmacia) were purchased from the 
SMBD-Jewish General Hospital pharmacy. Amifostine (AMF, 
Ethyol™) was a gift from MedImmune (The Netherlands). 116    The Open Orthopaedics Journal, 2008, Volume 2  Mwale et al. 
Animal Manipulation 
  All animal experiments were performed according to the 
guidelines of the Canadian Council on Animal Care. Lactat-
ing Sprague Dawley dams with 14 pups per female were 
purchased from Charles River Canada. At neonate day 10, 
rat pups were randomly divided into 7 groups of n=5 for 
saline, AMF+DOX, AMF+DOX+DXR, AMF, DOX, DXR 
and DOX+DXR treatments. Based on sexual maturity, 10 
days of age in rats are more like boys prior to 6 years old. 
Pups were injected once intraperitoneally with either phos-
phate buffered saline (saline) or drugs: AMF (50 mg/kg), 
DOX (3 mg/kg), DXR (60 mg/kg), DXR+DOX (60 mg/kg + 
3mg/kg), AMF+DOX (50 mg/kg + 3 mg/kg), or with 
AMF+DXR+DOX (50 mg/kg + 60 mg/kg + 3 mg/kg). AMF 
and DXR were injected 30 min prior to the DOX injection. 
The choice of the DOX and AMF concentrations is based on 
previous work in young rats [24] and accordingly to our pre-
vious work on female rats [22]. The concentration of DXR 
was 20-times the concentration of DOX, a ratio previously 
demonstrated to reduce DOX toxicity in adult rodent [25]. 
After injection, rat pups were returned to their mothers until 
weaning on neonate day 22. Rats were sacrificed on neonate 
day 38. 
Bone Mineral Density (BMD) and Bone Mineral Content 
(BMC) Analyses 
  Rats were sacrificed at day 38 (28 days post-injection). 
The PIXImus Bone Densitometer System #56069 (GE Lunar 
corporation) was used to measure bone densitometry using 
dual-energy X-Ray absorptiometry of bone tissue. The lum-
bar vertebraes were selected and their BMC (g) were meas-
ured by the PIXImus system. BMD (g/cm
2) was obtained by 
the ratio BMC/bone area. Bone area, expressed in cm
2, was 
the area selected to perform the BMC measurement. 
Micro Computed Tomography (microCT) 
  MicroCT data were acquired on a SkyScan T1072 X-Ray 
Microscope-Microtomograph (SkyScan, Aartselaar, Bel-
gium). The vertebrae samples were placed vertically in a 
precision object manipulator located between the X-Ray 
source (a microfocus sealed X-Ray tube operating at a volt-
age of 100 kV and current of 98 μA) and the detector (an X-
Ray charge-coupled device (CCD) camera). The samples 
were stepwise rotated around its axis, at a 0.9º angle. An 
image was acquired with exposition of 2,240 msec for every 
rotation step. A total of 206 images were obtained with a 
spatial resolution of 11.89 μm. The cross-sections along the 
specimen cylinder axis were reconstructed using Cone-Beam 
Reconstruction Software (SkyScan, Aartselaar, Belgium). 
Each cross-section was reduced in half size to facilitate the 
analysis, giving a voxel size of 21.89 m. CTScan and 3D 
Creator software (both from SkyScan) were used to analyze 
and create 3-dimension rendering models respectively. The 
actual material volume was calculated using the segmenta-
tion method. 
Statistical Analyses 
  Analyses of variance (ANOVAs) and Fisher’s tests were 
performed using StatView software (SAS Institute, Cary, 
NC). Significant differences were retained at p<0.05. 
 
RESULTS 
Body Weight 
  The body weight of male rats was significantly reduced 
by treatment with DOX, DXR, AMF, DOX+AMF, and 
DOX+AMF+DXR (Table 1). Treatment with DOX+DXR 
had no effect on body weight. 
Table 1. 
 
Drug  Body Weight at  
Sacrifice (g) 
Significant Difference 
vs Saline 
Saline  171 ± 7  - 
DOX  133 ± 9  p < 0.001 
DXR  145 ± 10  p < 0.001 
AMF  139 ± 7  p < 0.001 
DOX+DXR  173 ± 8  p > 0.05 
DOX+AMF  148 ± 8  p < 0.001 
DOX+DXR+AMF  152 ± 10  p = 0.001 
 
Bone Mineral Content (BMC) and Bone Mineral Density 
(BMD) of Lumbar Vertebral Bodies 
  BMC and BMD of the lumbar vertebrae were analyzed 
after treating male rats with different combinations of drugs 
(DOX, DXR, AMF, DOX+DXR, DOX+AMF, DOX+DXR+ 
AMF) and compared with the saline treatment (Fig. 1). In 
general, drugs inhibited both BMC (Fig. 1A) and BMD (Fig. 
1B). DOX treatment alone led to a significant 24% decrease 
in the BMC (p<0.01) as previously observed with female rats 
[22]. In order to better understand the protective effect of 
DXR, we decided to treat rats with DOX+DXR. Of special 
interest here was that DXR alone decreased BMC, but not 
significantly (p>0.05), by 11% (Fig. 1A). DXR had no effect 
on the inhibition of BMC by DOX while the combination of 
DOX+DXR decreased the BMC by 24% (p<0.01), as ob-
served with DOX alone. Treatment with AMF alone signifi-
cantly decreased the BMC by 35% (p<0.01). Adding AMF 
to DOX did not lead to a significant improved BMC but led 
to a significant 18% decrease (p<0.01) compared to saline 
control. Furthermore, the triple combination DOX+DXR+ 
AMF did not lead to an improvement in the BMC, but to a 
decrease of 23% (p<0.01). Surprisingly, the BMC is 17% 
less (p<0.05) in AMF treated rats than in DOX+AMF treated 
rats, suggesting that the effect was not synergistic. Since the 
above drugs have effects on the body weight of the rats (Ta-
ble 1), we also normalized the results to the weight of the 
animals, but this did not change the results. 
  We next tested the effect of the same drug combinations 
on BMD. Interestingly, the BMD was significantly de-
creased by all drug combinations, including the DXR treat-
ment alone (16%, p<0.01), when compared to the saline con-
trol (Fig. 1B). DOX treatment decreased the BMD by 18% 
(p<0.01). When combined with AMF, the toxicity of DOX 
was reduced (11%, p<0.05), whereas when combined with 
DXR, there was no change in DOX toxicity that remained at 
20% (p<0.01). The triple combination (DOX+DXR+AMF)  
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was the least detrimental but BMD was still significantly 
decreased by 11% (p<0.05) when compared to the saline 
control. The most important BMD decrease was observed for 
AMF-alone treatment (24%, p<0.01), which was signifi-
cantly lower than the DOX+AMF combination (11%, 
p<0.05) or the triple DOX+AMF+DXR combination (11%, 
p<0.05). 
Micro-Architecture of Lumbar Vertebral Bodies 
  To better understand the reduction in bone tissue, we also 
explore the effect of the different drug combinations on the 
vertebral bone architecture. 
 Fig.  (2) shows the ventral view of the 3-dimension recon-
struction of the male rat lumbar vertebrae obtained by Mi-
croCT technique. 
 
Fig. (1). Effect of single-, double-, and triple combination treatments on the lumbar vertebrae BMC and BMD in male rats. BMC (A) and 
BMD (B) were measured in animals at sacrifice with a PIXImus Bone densitometer System. Data are expressed as the mean ± standard de-
viation (SD). *p<0.05 vs saline control; **p<0.05 vs AMF treatment. 
 
Fig. (2). Effect of single-, double-, and triple combination treatments on the morphology of the lumbar vertebrae: a ventral view. The lumbar 
vertebrae were reconstructed in 3-dimension after micro computed tomography (micro CT) reconstruction and show the micro architecture of 
the lumbar vertebrae bone in the ventral view. The trabecular bone (TB) is presented in the white boxes. TP: transverse process; AP: acces-
sory process. 118    The Open Orthopaedics Journal, 2008, Volume 2  Mwale et al. 
  The trabecular bone (white rectangle) appeared slightly 
deteriorated by the following treatments: DXR, AMF, 
DOX+AMF, DOX+AMF+DXR. The quantitative analysis of 
the trabecular bone is presented in Table 2. The transverse 
process (TP), which is the bony intrusion on either side of 
the arch of the vertebrae, was reduced by AMF and 
DOX+AMF treatments. Interestingly, the triple combination 
of DOX+DXR+AMF showed a transverse process very simi-
lar to that of the saline control. The different treatments 
seemed to have no or few effects on the accessory process 
(AP), which is a small apophysis at the base of the transverse 
process. However, this small structure is more difficult to 
analyze since a slight rotation of the vertebrae may have an 
important effect on the appearance of the structure. 
  A lateral view of the rat lumbar vertebrae was also cre-
ated to highlight the effect of the different drug treatments on 
other parts of the rat vertebrae (Fig. 3). 
  The right lateral view of the vertebrae showed that the 
injected drugs had no effect on the lamina (L) that forms the 
dorsal wall of the vertebral foremen, except with the 
DOX+AMF and DOX+DXR+AMF treatments where the 
concavity of this structure was not well defined. The effect 
of drugs on the spinous process (SP), which is the dorsal 
projection of the vertebral arch, was very similar to what was 
observed for the transverse process with a decrease by the 
AMF and DOX+AMF treatments while the triple combina-
tion of DOX+DXR+AMF had no effect. Again, the different 
treatments seemed to have no or few effects on the accessory 
process (AP) that is, as mentioned before, more difficult to 
analyze. Finally, the different treatments had no effect on the 
posterior articular process (PP) of the male rat vertebrae. 
 Table  1 summarizes the quantitative results generated 
from MicroCT of trabecular bone of the lumbar vertebral 
bodies of male rats. The relative bone volume/tissue volume 
ratio (BV/TV) of the vertebral bodies was not affected by 
DOX, AMF, DOX+AMF, and DOX+DXR+AMF treatments. 
However, there was a non-significant trend toward decreased 
BV/TV with DXR and DOX+DXR (24 and 19%, respec-
tively), when compared to the saline control. In contrast, the 
BV/TV increased when rats were treated with DOX+AMF 
(1.53 fold, p<0.05) when compared to DXR treatment and 
tended to increase (1.44 times, p=0.07) when compared to 
DOX+DXR treatment. The bone surface/bone volume 
(BS/BV) ratios were not affected by the different treatments. 
The trabecular number (Tb.N) was decreased with DXR 
(19%, p<0.05) and tended to decrease with DOX+DXR 
(15%, p<0.09), when compared to saline control. Tb.N was 
also lower in DXR-treated rats compared to DOX-treated 
rats (22%, p<0.05). DOX+AMF increased the Tb.N of male 
rats when compared to the DXR treatment (1.37 times, 
p<0.05) and tended to increase this Tb.N when compared to 
the DOX+DXR-treated animals (1.30 times, p=0.06). 
  The trabecular separation (Tb.Sp), which is the thickness 
of the marrow spaces between trabecular structures, was not 
significantly affected by the different treatments, except for 
the DOX+AMF treatment that significantly decreased Tb.Sp 
by 11% (p<0.02) and 14% (p<0.005) when compared to DXR 
and DOX+DXR treatments, respectively. 
DISCUSSION 
  Children with cancers may be more highly susceptible to 
secondary toxicities than adults because they are actively 
growing [20]. The increased numbers of childhood cancer 
 
Fig. (3). Effect of single-, double-, and triple combination treatments on the morphology of the lumbar vertebrae: a lateral view. The lumbar 
vertebrae were reconstructed in 3-dimension after micro computed tomography (micro CT) reconstruction and show the micro architecture of 
the lumbar vertebrae bone in the right lateral view. PP: posterior articular process; SP: spinous process; AP: accessory process; L: lamina. Dexrazoxane and Amifostine on the Vertebral Bone Quality  The Open Orthopaedics Journal, 2008, Volume 2    119 
survivors is a consequence of improvement in cancer thera-
pies which allow more children to survive their cancer. 
These same therapies can reduce bone mineralization, reduce 
final height and sitting height of cancer survivors and in-
crease the incidence of fracture [7, 8]. At high cumulative 
dose (550 mg/m), DOX increases dramatically the risks of 
developing cardiac side effects, including congestive heart 
failure, dilated cardiomyopathy, and death [13-15]. Reactive 
oxygen species, generated by the interaction of doxorubicin 
with iron, can also damage the myocytes, causing 
myofibrillar loss and cytoplasmic vacuolization [11, 12]. 
However, little is known about the indirect or direct effects 
of anti-cancer drugs, such as DOX, and of cytoprotective 
agents, such as DXR and AMF, on the spine. Moreover, the 
effect of DOX, with or without DXR and/or AMF, on bone 
of children is not well understood. We showed recently that 
a single injection of DOX in young female rats is associated 
with low bone turnover resulting in vertebrae bone growth 
deficits [22, 23]. However, little work has been done to in-
vestigate the effect of these drugs on bone mass of the male 
vertebrae even though some differences in drug response 
between the genders have been observed [13-15, 23]. Some 
studies suggest that young females have a greater incidence 
for DOX-induced cardiotoxicity than young males [13-15] 
although a gender bias was not detected in other studies [10, 
25]. The aim of this study was to determine whether admini-
stration of AMF and/or of DXR would prevent any DOX-
mediated bone damage in the young growing male rats. 
  The present data indicate that DOX selectively decreased 
BMD and BMC accrual in the lumbar vertebrae of male rats 
and that neither DXR nor AMF were able to prevent these 
reductions. Furthermore, AMF treatment alone appears to be 
worse than DOX treatment. This is contrary to what was 
expected and to what was found in a previous study using 
knees of rats. In this study, seventy-two weanling rats had 
their right knee irradiated with single fraction 17.5 Gy, 
whereas the left leg was used as an internal control [26]. The 
results indicated that the animals receiving AMF had BMD 
that was closer to controls only adjacent to the chondro-
osseous junction at 0.5, 2, and 3 weeks. Similarly, AMF had 
a significant protective effect against DOX-induced early 
alopecia in young rats [27]. However, in this study AMF did 
not protect young rats against the late toxic effects of DOX 
on linear growth, body weight, plasma leptin levels, and 
heart or testicular tissue. AMF treatment may therefore not 
always protect from DOX toxicity. Moreover, the decrease 
of both BMC and BMD by AMF is not sex-dependent since 
we observed the same tendency in our previous studies in 
females [22], whereas in this case, the BMD and BMC val-
ues were most significantly decreased by DOX treatment. 
Further studies are necessary to determine if these changes 
correlate with changes in serum markers of bone turnover 
such as alkaline phosphatase and C-telopeptides. These re-
sults have implications in relation to the safety of AMF 
treatment and its mechanisms of action before wider clinical 
use of this drug in pediatric cancer patients is recommended. 
As AMF is not clinically used on its own, further studies are 
needed to better characterize the effects of AMF on bone 
growth, mineral density, and architecture. Moreover, long-
term evaluation will be necessary to determine the possible 
reversibility of the effect of these drugs on bone architecture. 
  Micro-architecture data in male rats treated with DXR 
and with the two double combinations treatments are very 
interesting. It has been shown that decreases in the BV/TV 
ratio and in Tb.N accompanied with an increase in Tb.Sp 
were correlated with bone fracture severity in vertebrae of 
osteoporotic women [3]. In the present study, DXR treatment 
negatively affected the trabecular bone structure, with a sig-
nificant effect on Tb.N and a mild effect on BV/TV. This 
suggests an increased risk of fracture in the DXR-treated 
animals. This remains to be investigated with biomechanical 
studies. This effect may not be due to the DNA topoi-
somerase II activity. Both DOX and DXR reduce DNA 
topoisomerase II activity. 
  PIXImus analyzes simultaneously the properties of both 
the cortical and the trabecular bones, without discrimination 
(Fig. 1). Micro CT analyzes only the characteristics of the 
trabecular bone (Table 2). Since, in the present study, both 
cortical and trabecular bone characteristics measured by the 
PIXImus (BMD and BMC) were significantly affected by 
drug treatments, whereas the trabecular bone characteristics 
alone (measured by micro CT) was less significantly affected 
by the same drugs, it appears that in male rats, the cortical 
bone was the most affected by the single-, double-, and tri-
ple-therapies. On the contrary, the age-matched female rats 
we previously studied [22] showed significant defects for all 
drugs tested in both lumbar vertebrae BMD/BMC and micro-
architecture. This might be explained by sex effects. In hu-
mans, BMD values in lumbar spines of girls have been 
shown to be higher when compared with age-matched boys. 
Boys showed higher BMD values preferentially for cortical 
sites [13], probably affecting as well the micro-architecture 
at these sites. However, since girls and boys mature at differ-
Table 2. 
 
  BV/TV (%)  BS/BV (mm
-1) Tb.N  (mm
-1) Tb.Sp  (mm) 
Saline  21.5 ± 3.4  57.9 ± 7.5  2.3 ± 0.3  0.25 ± 0.01 
DOX  22.3 ± 1.5  56.6 ± 1.0  2.4 ±0.1  0.25 ± 0.01 
DXR  16.3 ± 1.9  65.5 ± 4.6  1.8 ± 0.2§  0.26 ± 0.01 
DOX+DXR  17.3 ± 2.9  62.9 ± 5.0  1.9 ± 0.2  0.27 ± 0.01 
AMF  21.9 ± 5.1  57.5 ± 7.8  2.3 ± 0.4  0.25 ± 0.02 
DOX+AMF  24.9 ± 5.8*  53.6 ± 9.3  2.5 ± 0.4*  0.23 ± 0.01*‡ 
DOX+AMF+DXR  21.5 ± 4.1  58.0 ± 6.4  2.3 ± 0.4  0.25 ± 0.01 120    The Open Orthopaedics Journal, 2008, Volume 2  Mwale et al. 
ent rates, further studies are necessary to definitively con-
clude on the sex-dependent effect of these drugs in human. 
  The mechanisms for sex specificity are not clear. We 
speculate that the sex-dependent specificity of DOX, DXR 
and AMF on bone tissue could be, at least in part, caused by 
sex steroid hormone levels. Although this hypothesis re-
mains highly speculative and requires further investigations, 
differences in sex steroids remains a potential mechanism for 
differences in the response of these pre-pubertal males and 
females. It must be noted that, the level of sex steroid hor-
mones is likely very low in day 10 neonate rats, the time of 
injection in this study. Nevertheless, this information would 
be useful in designing better cancer combination therapies 
that do not lead to bone deterioration. 
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